Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728023 · ClinicalTrials.gov registry record · Phase 1
A Study of AZD4205 in Healthy Adult Subjects
A Phase 1 study, sponsored by Dizal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT03728023 is a Phase 1 study that has completed, run by Dizal Pharmaceuticals. The registered enrollment target is 66 participants.
The verdict
NCT03728023, a Phase 1 study, has completed, sponsored by Dizal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study is to assess the safety, tolerability, pharmacokinetics of AZD4205 following single and multiple ascending dose in healthy adult subjects, and to assess the effect of food on the pharmacokinetics of AZD4205.
Interventions
- DRUG Placebo
- DRUG AZD4205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2019-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03728023
The ClinicalTrials.gov registry entry for NCT03728023 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03728023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03728023 about?
NCT03728023 is a clinical study titled "A Study of AZD4205 in Healthy Adult Subjects". This study is to assess the safety, tolerability, pharmacokinetics of AZD4205 following single and multiple ascending dose in healthy adult subjects, and to assess the effect of food on the pharmacokinetics of AZD4205.
What is the current status of trial NCT03728023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2018-11-12. Estimated completion is 2019-08-20.
What interventions are being tested in trial NCT03728023?
The interventions under investigation include: Placebo (DRUG), AZD4205 (DRUG).
Who is sponsoring clinical trial NCT03728023?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.